2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease

Details for Australian Patent Application No. 2005309760 (hide)

Owner Merck & Co., Inc.

Inventors Stanton, Matthew G.; Selnick, Harold G.; Moore, Keith P.; Stauffer, Shaun R.; Nantermet, Philippe G.; Rajapakse, Hemaka A.; Barrow, James C.; Stachel, Shawn J.; Vacca, Joseph P.

Agent Spruson & Ferguson

Pub. Number AU-A-2005309760

PCT Pub. Number WO2006/057945

Priority 60/653,037 15.02.05 US; 60/693,271 23.06.05 US; 60/630,539 23.11.04 US

Filing date 18 November 2005

Wipo publication date 1 June 2006

International Classifications

C07D 413/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

Event Publications

31 May 2007 PCT application entered the National Phase

  PCT publication WO2006/057945 Priority application(s): WO2006/057945

3 December 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005309761-Tubulin binding anti cancer agents and prodrugs thereof

2005309758-Spinal plug for a minimally invasive facet joint fusion system